Difference between revisions of "Cabazitaxel (Jevtana)"
Jump to navigation
Jump to search
m |
m |
||
| Line 23: | Line 23: | ||
==History of changes in Health Canada indication== | ==History of changes in Health Canada indication== | ||
*2011-06-06: Initial notice of compliance for the treatment of patients with castration resistant (hormone refractory) metastatic [[prostate cancer]] previously treated with a docetaxel containing regimen. | *2011-06-06: Initial notice of compliance for the treatment of patients with castration resistant (hormone refractory) metastatic [[prostate cancer]] previously treated with a docetaxel containing regimen. | ||
| − | + | ==History of changes in PMDA indication== | |
| + | *2014-07-04: Initial approval for the treatment of [[prostate cancer]]. | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' XRP6258, TXD258, RPR116258A | *'''Code names:''' XRP6258, TXD258, RPR116258A | ||
| Line 41: | Line 42: | ||
[[Category:FDA approved in 2010]] | [[Category:FDA approved in 2010]] | ||
[[Category:Health Canada approved in 2011]] | [[Category:Health Canada approved in 2011]] | ||
| + | [[Category:PMDA approved in 2014]] | ||
Revision as of 23:19, 9 June 2023
General information
Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization, inhibiting interphase/mitosis processes.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Cabazitaxel (Jevtana) package insert[1]
- Cabazitaxel (Jevtana) patient drug information (Chemocare)[4]
- Cabazitaxel (Jevtana) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2010-06-17: Initial approval in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen. (Based on TROPIC)
- 2017-09-14: Approved at a lower dose (20 mg/m2 every 3 weeks) in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. (Based on PROSELICA)
- 2020-12-18: Approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. (Based on CARD)
History of changes in EMA indication
- 2011-03-17: Initial marketing authorization as Jevtana.
History of changes in Health Canada indication
- 2011-06-06: Initial notice of compliance for the treatment of patients with castration resistant (hormone refractory) metastatic prostate cancer previously treated with a docetaxel containing regimen.
History of changes in PMDA indication
- 2014-07-04: Initial approval for the treatment of prostate cancer.
Also known as
- Code names: XRP6258, TXD258, RPR116258A
- Brand names: Cabapan, Cabaxan, Cabazither, Cabtana, Cazat, Jevatax, Jevtana, Kabanat, Procabazi, Qtervaxia, Z-Texel